InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. The company has research collaboration and license agreement with Eli Lilly and Company to develop new medicines. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Frequently asked questions
What sector does Innocare Pharma Ltd (9969) operate in?
Innocare Pharma Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Innocare Pharma Ltd (9969) current stock price?
As of the latest data, Innocare Pharma Ltd stock price is HK$11.61, with a previous close of HK$11.77. Innocare Pharma Ltd lost -HK$0.16 in the last trading session, representing a -1.36% loss.
What is Innocare Pharma Ltd (9969) current market capitalization?
Innocare Pharma Ltd market cap is approximately 17.34 billion.
What is Innocare Pharma Ltd (9969) Earnings Per Share (EPS)?
The trailing EPS is HK$0.58, and the forward EPS is HK$0.18.
What is Innocare Pharma Ltd (9969) Price-to-Earnings (P/E) ratio?
Innocare Pharma Ltd current P/E ratio is 20.08, with a forward P/E of 64.5.
What is Innocare Pharma Ltd (9969) EBITDA?
Innocare Pharma Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 102.72 million.
Does Innocare Pharma Ltd (9969) pay dividends?
No. Innocare Pharma Ltd does not pay a dividend.
When is Innocare Pharma Ltd (9969) next earnings report?
Innocare Pharma Ltd is expected to release its next earnings report on December 31, 2026.
What is Innocare Pharma Ltd (9969) beta (volatility) score?
Innocare Pharma Ltd has a beta of 0.367, indicating lower volatility than the overall market.
